Bengaluru-based Centre for Cellular And Molecular Platforms (C-CAMP), an initiative of Department of Biotechnology (DBT), is launching the 4th edition of CARB-X supported AMR Quest.

The Quest is a unique nation-wide platform dedicated exclusively to innovations in the Antimicrobial Resistance (AMR) domain. It aims to identify, reward, and nurture Indian innovators developing solutions to tackle AMR with a specific focus on ESKAPE Pathogens- a group of opportunistic pathogens consisting of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.

CARB-X and C-CAMP have partnered to bolster ecosystem development across three funding pillars: preventatives, diagnostics and therapeutics. 

AMR Quest 2023 will be open to students, early-stage, and late-stage startups/MSMEs. Ideas and innovations in the domains of non-traditional therapeutics, preventatives, diagnostics, and direct acting small molecule therapeutics will be accepted.

Winners of the quest will be rewarded with mentorship through an accelerator programme called C-CAMP AMR Accelerator Program -2023. The accelerator will provide an opportunity to develop the solution both as a technology and a business venture with structured mentorship in the domains of science, business, regulation, patent law, fundraising, etc.

Additionally, winners will have the opportunity to participate in AMR Innovators school -2023, where they will engage with leading experts across disciplines, collaborate with like-minded peers, and further enhance their knowledge and skills in the field of AMR. Innovators will also be given global exposure through paid participation in any one global conference in the field.